Estrogen replacement therapy in women has shown a protective effect on the development of colonic carcinomas. Gender-related differences in the development of colonic carcinomas have also been reported. Estrogen receptor-b (ERb) is expressed in colon carcinomas and has shown prognostic value in colon cancer patients. This study investigated an ERb 3 0 non-coding polymorphism associated with transcriptional activity to determine clinical outcome in patients with metastatic colon cancer. Genomic DNA from 318 metastatic colon cancer patients, 177 males and 141 females, were collected from 1992 to 2003. These patients were analyzed for CA repeat polymorphism of the ERb gene. Gender-related survival differences were associated with an ERb (CA) n repeat polymorphism (P for interaction ¼ 0.003, the likelihood ratio test). Female patients with any short o22 (CA) n repeat alleles had shorter overall survival (OS) compared with female patients who had both long X22 (CA) n repeat alleles. In the male patients, the opposite OS difference was found. This study supports the role of an ERb (CA) n repeat polymorphism as a prognostic marker in metastatic colon cancer; however, this prognostic factor had opposite implications based on gender.
Introduction
Colorectal cancer is the second most common cause of cancer-related death in the United States. In 2009, an estimated 106 100 new cases will be diagnosed and 49 920 deaths will occur. 1 Recent evidence suggests that there are gender-related differences in the development of colonic carcinomas. Women of all ages are less likely to develop colon cancer. [2] [3] [4] Animal models have also shown that male rats exposed to experimental carcinogens have a higher risk of developing colon cancer compared with female rats. 5, 6 Large comprehensive studies such as the WHI (Women's Health Initiative) have shown conclusively that postmenopausal women treated with estrogen replacement therapy have a significant reduction in their relative risk of developing colon cancer. 7, 8 The molecular mechanisms by which estrogen replacement therapy exerts its protective effect against colon cancer are not understood. However, the presence of sex hormones and their receptors in the colon may influence the development of colon cancer differently in men and women.
Estrogen receptor-b (ERb) is expressed in colonic tissue. 9 Loss of ERb expression has been linked to malignant transformation 10 and advanced Dukes stage. 11 Colon cancer cell lines expressing ERb treated with estrogen have shown induction in apoptosis. 12 ERb expression in the colon is also associated with regulation of important prognostic markers, such as thymidylate synthase, survivin, telomerase, 13 adenomatosis polyposis coli tumor-suppressor gene 14 and p38/ mitogen-activated protein kinase. 15 Multiple review articles indicate that loss of ERb expression is a common step in the development of colonic carcinoma. [16] [17] [18] Within the ERb gene, located on chromosome 14q22-32, is a polymorphic dinucleotide (CA) n repeat in the 3 0 noncoding region. In vitro studies of vector insertion of short (CA) n repeats show an association with increased ERb protein expression. 19 Women with increased numbers of ERb CA repeats have a sixfold increase in the risk of developing colon cancer. 20 The number of CA repeats in the ERb polymorphism is also associated with higher bone mineral density in premenopausal women 21 as well as with increased androgen hormone levels and increased sex steroid-binding globulin levels. 22, 23 On the basis of this information, we tested the hypothesis that genetic variation at the ERb locus may be associated with gender-related survival in patients with metastatic colon cancer.
Materials and methods

Eligible patients
A total of 318 patients with metastatic colon cancer treated at the University of Southern California/Norris Comprehensive Cancer Center (USC/NCCC) or the Los Angeles County þ University of Southern California Medical Center (LAC þ USCMC) between 1992 and 2003 were eligible for this study. This population included only metastatic or recurrent colon cancer patients. All patients in this study signed informed consents and enrolled in protocols designed to study the molecular determinants of colon cancer. These protocols permitted blood collection (protocol 0S-99-10) and/or tissue collection (protocol 0S-00-15).
All enrolled patients were followed with an institutional database. Patient information was collected through database review and retrospective chart review when additional patient information was necessary. A large number of the patients (220/318 ¼ 69%) were initially treated at an outside institution until, because of failure to respond to previous treatment, they were referred to USC/NCCC or LAC þ USCMC for future treatments. The end point of this study was overall survival (OS). The OS was determined by calculating the difference between the date of first treatment at USC/NCCC or LAC þ USC and the date of last follow-up appointment or date of death from disease.
All 318 patients were enrolled in at least one chemotherapy clinical trial while being treated at this institution (USC/NCCC or LAC/USCMC). All patients were treated with 5-fluorouracil-based chemotherapy regimens. Response to chemotherapy was not investigated as an end point for this study. This is a heavily pretreated cohort with 20 patients (6%) treated with one line of chemotherapy, 19 patients (6%) treated with two different chemotherapy regimens, 183 patents (58%) treated with three different chemotherapy regimens and 96 patients (30%) treated with X4 chemotherapy regimens. Although the treatment regimens varied among patients, the majority of patients were exposed to similar chemotherapies. All 318 patients (100%) received treatment with 5-fluorouracil, 298 patients (94%) received treatment with 5-fluorouracil/irinotecan (CPT-11) and 279 patients (88%) received treatment with 5-fluorouracil/oxaliplatin.
Laboratory methods DNA extraction. Peripheral blood and paraffin-embedded tissue samples were collected from each patient. Genomic DNA was extracted from whole blood or paraffinized tissue using the QiaAmp kit (Qiagen, Valencia, CA, USA). Genomic DNA was obtained from peripheral blood for 314 of the patients. There were four samples in which peripheral blood was not available and, therefore, genomic DNA was obtained from paraffin-embedded tissue. These 318 genomic DNA samples were used to analyze the ERb (CA) n repeat polymorphism.
Genotyping of ERb (CA) n repeat polymorphism
The PCR was performed with oligonucleotide primers (5 0 -GGTAAACCATGGTCTGTACC-3 0 and 5 0 -AACAAAATGTT GAATGAGTGGG-3 0 ) designed to amplify a polymorphic (CA) n repeat in the flanking region of the human ERb gene. The reaction was carried out in a final PCR volume of 15 ml containing 100 ng of genomic DNA, 200 mM deoxyribonucleotide triphosphates, 1.0 mM 5 0 33P-gATP end-labeled reverse primer, 1.0 mM unlabeled forward primer, 0.75 U Taq polymerase (Perkin Elmer, Waltham, MA, USA) and PCR buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 ). The reaction was carried out for 35 cycles with 94 1C (1 min) denaturation, 60 1C (1 min) annealing and 72 1C (1 min) extension. The reaction products were separated on a 6% denaturing polyacrylamide DNA sequencing gel, vacuum blotted for 1 h at 80 1C and exposed to an XAR film (Eastman-Kodak, Rochester, NY, USA) for 6-8 h. The exact number of the CA repeats was confirmed by direct sequencing.
ERb intratumoral mRNA gene expression In our cohort of 318 patients there were only a total of 64 patients with available paraffin-embedded tumor blocks. All 64 patients with available paraffin-embedded tumor blocks were analyzed for ERb intratumoral mRNA gene expression. Paraffin-embedded tumor blocks were reviewed for quality and tumor content. For each sample, microdissection of intratumoral tissue was extracted, and RNA isolation and complementary DNA synthesis were performed, followed by real-time PCR quantification of mRNA expression as described. 24 Survival differences in ERb polymorphisms related to gender
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Statistical analysis
The primary end point of this study was OS. The OS was defined as the time period between the date of first treatment at USC/NCCC or LAC þ USC for their metastatic disease and date of death or the date of last follow-up appointment. Patients who were still alive at the last followup were censored at that time.
The associations between sex and other baseline demographic and clinical characteristics were examined using contingency tables and the w 2 test or when appropriate, Fisher's exact test. The ERb (CA) n repeat polymorphism was categorized into two groups using the most frequent (CA) n as a cutoff point: any alleles with o22 (CA) n and both alleles with X22 (CA) n in the similar way as previous studies. 22, 23, 25 The differences in expression levels of two ERb isoforms, ERb1 and ERb5, by ERb (CA) n repeat polymorphism and sex were examined using the Mann-Whitney U-test. The associations of ERb (CA) n repeat polymorphisms with OS were analyzed individually using Kaplan-Meier plots and the log-rank test. In the univariate analysis, the estimate of relative risk with 95% confidence intervals was based on the log-rank test. 26, 27 Multivariate analysis using Cox proportional hazards regression model was performed to evaluate the association between ERb polymorphism and OS when adjusted for baseline characteristics. Interactions between sex and ERb polymorphism were examined using stratified models and were tested by comparing corresponding likelihood ratio statistics between the baseline and nested Cox proportional hazards models that included the multiplicative product terms. 28 
Results
This population contained a total of 318 patients: 141 females (44%) and 177 males (56%). Within the two populations, males and females, there were no statistically significant variations with regard to age, racial/ethnic makeup, location of the primary tumor or location of first metastatic site. The median age at the time of diagnosis was 58 years with a range of 25-86 years of age. The racial-ethnic distribution of study participants was 234 Caucasians (73%), 43 Asians (14%), 24 Hispanics (8%), 15 Blacks (5%) and 2 Native Americans (1%). The location of the primary tumor within the colon was as follows: 144 left-sided tumors (45%), 124 right-sided tumors (39%) and 50 (16%) in which the side was unknown. The location of the first metastatic site for 156 (49%) patients was the liver, for 56 (18%) intraabdominal sites, for 46 (15%) other (lung, bone, stomach, spleen, pancreas or gallbladder) metastatic sites, and there were 57 (18%) patients who presented with two or more metastatic sites at the onset of metastatic disease (Table 1) .
OS differences in this population were not associated with gender differences, racial-ethnic distribution, location of primary tumor or location of first metastatic lesion. The ERb (CA) n repeat polymorphism was not associated with the age of onset of metastatic disease, location of primary tumor or location of first metastatic lesion (data not shown).
ERb (CA) n repeat polymorphism
The extracted genomic DNA was evaluated for the ERb (CA) n repeat polymorphism and the assay was successful in 315 of the 318 cases. There were three cases in which the genomic DNA was either consumed or degraded. In all, 18 different alleles of the ERb gene polymorphism were identified, comprising PCR products of 137-177 base pairs, which is 9-29 (CA) n repeats ( Figure 1 ). The most predominant allele was the 22 (CA) n repeat (163 base pairs). Asians were more likely to carry shorter (CA) n repeats of the ERb gene compared with other ethnic groups (Po0.001, Figure 1 ). The frequency of ERb (CA) n repeat allelic distributions were similar to other studies performed in Caucasian populations. 22, 25, 29 The ERb (CA) n repeats were divided into two subgroups. The cutoff for these groups was 22 ERb (CA) repeats, which was determined by previous publications. 22, 25, 29 That is, patients with o22 repeats were in the first subgroup, and patients with at least 22 repeats were in the second subgroup. Here, 22 repeats was chosen as the cutoff because it was the most frequent allele, and has been used as a cutoff in previous studies. This approach was used to evaluate the effect that the polymorphism had on OS among all 315 study participants: 71% (224/315) of the patients had at least one short allele o22 (CA) n repeat, whereas 29% (91/315) of the patients had two long allele X22 (CA) n (Table 2) ; however, when the patient population was separated by gender, the (CA) n repeat genotypes were associated with OS (Table 2) . Female patients with any short o22 (CA) n repeat alleles (n ¼ 101) had shorter OS (median OS ¼ 14.1 months) compared with the female patient group who had two long X22 (CA) n repeat alleles (n ¼ 39; median OS ¼ 18.4 months; P ¼ 0.05, multivariate analysis; Table 2 ). In the male patients the opposite OS difference was found. The male patients with any short o22 (CA) n repeat allele (n ¼ 123) had a longer OS (median OS ¼ 13.6 months) compared with males who had two long X22 (CA) n repeat alleles (n ¼ 52; median OS ¼ 10.3 months; P ¼ 0.014, univariate analysis; Table 2 ). Therefore, as a prognostic factor this ERb (CA) n repeat polymorphism had opposite implications based on gender (P for interaction ¼ 0.003).
Patients with two long X22 (CA) n repeat alleles showed a large shift in OS based on whether the patient was male (median OS ¼ 10.3 months; n ¼ 52) or female (median OS ¼ 18.4 months; n ¼ 39; Table 2 and Figure 2 ). However, patients with any short o22 (CA) n repeat allele had a median OS that was similar; males 13.6 months of OS (n ¼ 123) and females 14.1 months of OS (n ¼ 101; Table 2 ).
Intertumoral mRNA gene expression of ERb levels in association with ERb (CA) n repeat polymorphism
The intertumoral mRNA gene expression of ERb levels were associated with the ERb (CA) n repeat polymorphism. There was a significant difference in ERb1 expression values by ERb (CA) n repeat polymorphism (P ¼ 0.043, Mann-Whitney test). The tumors with any short o22 (CA) n repeat alleles had higher intratumoral ERb1 mRNA expression value. A total of 64 patients had paraffin-embedded tumor blocks available. Of these, 47 patients had at least one short o22 (CA) n repeat allele. These 47 patients had a median mRNA expression level of 1.88 (range 0.01-195.09). This was compared with the 17 patients with both long X22 (CA) n repeat alleles that had a median mRNA expression level of 1.14 (range 0.01-4.47). Therefore, the tumors with any short o22 (CA) n repeat alleles had higher ERb1 expression level (median 1.88) compared with both long X22 (CA) n repeat alleles that had a lower expression level of 1.14 (P ¼ 0.043, Mann-Whitney test).
ERb1, ERb2, ERb3, ERb4 or ERb5 expression values revealed no associated differences of intratumoral mRNA expression based on gender (P ¼ 0.24). Although ERb1 expression values were associated with ERb (CA) n repeat polymorphism (P ¼ 0.043, Mann-Whitney test), there were no similar significant associations with ERb (CA) n repeat polymorphism and ERb2, ERb3, ERb4 or ERb5 expression values.
Androgen receptor polymorphism analysis and ERb haplotype
We also analyzed a CA repeat polymorphism in the androgen receptor, as well as ERb haplotype. Neither marker was significantly associated with clinical outcome (data not shown).
Discussion
This study has investigated genetic variation in the sex steroid hormone receptor ERb in metastatic colon cancer patients. Gender-related survival differences were associated with an ERb (CA) n repeat polymorphism (P for interaction ¼ 0.003, the likelihood ratio test). Female patients with any short o22 (CA) n repeat allele had shorter OS compared with female patients who had two long X22 (CA) n repeat alleles. In the male patients, the opposite OS difference was found.
Our patient population had a frequency of ERb (CA) n repeat allelic distributions similar to that of other study populations (Figure 1) . 22, 25, 29 Demographic information for age, ethnicity and location of tumor was collected for our patient population and no associations were found (Table 1) . This indicates that our findings are not due to a sampling error.
Evidence is accumulating to support the role of sex steroid hormones in the development of colonic carcinomas. One explanation is the known protective effect that estrogen has against the development of colon cancer. It has been clearly shown that menopausal women treated with estrogen replacement therapy have a significant reduction in both their relative risk and their relative rate of developing colon cancer. 7, 8 In addition, women of all ages are less likely to develop colon cancer. [2] [3] [4] Generally speaking, females have higher levels of estrogens and lower levels of androgens; the opposite is true in males.
In this population OS differences associated with the ERb polymorphism were only observed when the population was separated by gender. This could imply that ERb has a fundamentally different role among genders. One study by Foley et al. 10 found that selective loss of ERb protein expression led to malignant transformation in colonic tissues. ERb is the major estrogen receptor expressed in the colon, 9 and multiple review articles indicate that loss of ERb expression is a common step in the development of colonic carcinoma. [16] [17] [18] This information indicates that the presence of ERb expression in the colon has a protective effect. Combine this information with the known protective effect of estrogen replacement therapy in menopausal women and there is strong indication that both estrogen hormone and the presence of ERb have a protective effect on the development of colonic carcinoma.
The ERb (CA) n repeat polymorphism has functional significance. One study by Ugai et al. 19 found that in vitro insertion of short (CA) n repeats showed an association with increased ERb protein expression. In addition, our study has shown that patients with any short o22 (CA) n repeat alleles had a higher intratumoral ERb1 gene expression value compared with patients with homozygous long X22 (CA) n repeat alleles (P-value ¼ 0.043). To our knowledge, this is the first study to link this ERb (CA) n repeat polymorphism to ERb mRNA expression. Both our study and the study by Ugai et al. 19 indicate that short o22 (CA) n repeat alleles have higher ERb expression and the homozygous long X22 (CA) n repeat alleles have lower relative ERb expression. Male ER β (CA)n < 22 (n=123)
Male ER β (CA)n ≥ 22 (n=52) P for interaction = 0.003 Figure 2 Gender-related overall survival for ERb long alleles X22 and short o22 (CA) n repeats.
The mechanism of how this ERb (CA) n repeat polymorphism effects the ERb mRNA expression is not known and further in vitro and in vivo studies are indicated. The ERb (CA) n repeat polymorphism is clinically significant. This ERb (CA) n repeat polymorphism has been positively associated with a diverse range of conditions, including hormonal regulation, 22, 23 bone mineral density, 21, [30] [31] [32] Alzheimer's disease 29 and blood pressure. 33 In addition, epidemiologic studies have shown that women with increased numbers of ERb CA repeat polymorphisms have a sixfold increase in the risk of developing colon cancer. 20 In our study of the ERb polymorphism in the male population, the findings were consistent with our hypothesis. The male population who had two long X22 (CA) n repeat alleles associated with low relative ERb expression had worse OS (median OS ¼ 10.3 months) compared with male patients with any short o22 (CA) n repeat allele (median OS ¼ 13.6 months; Table 2 ). Previous data have established the protective effect of ERb against the development of colon cancer. [16] [17] [18] Our data in the male population are consistent with this ERb protective effect and showed that after the development of colon cancer, males with increased ERb expression had a better prognosis. Our data indicate that the short (CA) n ERb polymorphism, which has increased ERb expression, is a marker of more favorable clinical outcome in males with colon cancer. It is possible that in males ERb acts as an apoptotic factor in both normal and neoplastic colonic mucosa. Additional studies are needed to better characterize this effect.
Our study found that female patients who had two long X22 (CA) n repeat alleles, associated with low relative ERb expression, had a better OS (median OS ¼ 18.4 months) compared with female patients with any short o22 (CA) n repeat allele that is associated with increased relative ERb expression (median OS ¼ 14.1 months; Table 2 ). Given the protective effect of the relative expression of ERb on the development of colonic carcinoma, the female population had exactly the opposite OS from what would have been expected.
The patients with two long X22 (CA) n repeat alleles have lower relative ERb expression. 19 As expression of ERb has a protective effect on the development of colonic carcinoma, [16] [17] [18] the long repeats should have worse OS. However, this was not observed in the females. Although there is an established protective effect of ERb against the development of colon cancer, [16] [17] [18] our data would indicate that after the development of colon cancer, increased ERb expression in female patients is a marker of poor prognosis. The short (CA) n repeat ERb polymorphism is associated with increased ERb expression and is a marker for poor prognosis in females with colon cancer. It is possible that although ERb acts as an apoptotic factor in female normal colonic mucosa, after neoplastic transformation an alteration in ERb may occur to allow ERb to function as a neoplastic growth factor. The molecular mechanisms of ERb function in tumors are currently unclear. Future studies are needed to explore molecular function of ERb polymorphisms in colonic neoplasms and to confirm our findings.
Our data that a functional ERb polymorphism is associated with opposite prognostic implications based on gender are consistent with other studies. Opposite prognostic implications in relation to ERb expression in men and women have been shown in lung cancer. 34 Furthermore, our previous findings showed the same opposite effect of two functional polymorphisms of epidermal growth factor receptor (EGFR) in predicting clinical outcome based on gender in the same patient cohort. 35 In this study the males followed the expected prognostic implication that EGFR polymorphisms are associated with increased expression of EGFR and have a worse clinical outcome. However, the female patients with the same polymorphisms had exactly the opposite effect.
Another explanation for women not showing the expected ERb protective effect could have to do with intermediates that result in different activation in males and females. For example, EGFR has been shown to interact in an opposite manner based on sex-specific steroid signaling. 36 EGFR has been shown to have bidirectional signaling with both estrogen 37 and androgen receptors. 38, 39 If tumor-specific expression of ERb and EGFR in the colon were inversely related, then regulation of estrogen's protective effect would also be inversely related. This might contribute to the unexpected inverse survival benefit observed in our female patient population. Future studies are necessary to explore the possible molecular interactions that may exist between sex hormone pathways involving ERb and EGFR in the colon. Our data may have implications for treatment. There have been indications that men and women respond differently to treatment for colon cancer. A phase III clinical trial (EORTC 05963) in metastatic colorectal cancer found that gender was associated with a treatment-specific inversion of OS benefit among males and females. 40 In animal models of known positive ERb colon cancer, known selective estrogen receptor modulator has been shown to interact with ERb protein and mRNA expression to give a chemopreventive effect. 41 This may indicate that treatment of human colon cancer may be responsive to selective estrogen receptor modulators. Lung cancer, similar to colon cancer, has expression of primary ERb and has large numbers of patients represented from both genders. In a lung cancer clinical trial, fulvestrant, an anti-estrogen, has shown antitumor activity and clinical responses to this treatment. 42 In summary, this study supports the role of a 3 0 noncoding (CA) n repeat polymorphism of the ERb gene as a prognostic marker in metastatic colon cancer. The ERb (CA) n repeat polymorphic variant had opposite prognostic implications based on gender. To our knowledge, this is the first study that shows a relationship between ERb polymorphisms and gender-related survival in colon cancer. However, these preliminary findings still need to be replicated in larger studies, as well as additional confirmatory in vitro and in vivo functional investigations of this polymorphism are warranted.
